158 related articles for article (PubMed ID: 15351603)
1. Intracranial metastatic prostate carcinoma presenting as intermittent double vision.
Saito Y; Kondo Y; Shimizu H; Kunimoto K; Nishimura T
Urology; 2004 Sep; 64(3):589-90. PubMed ID: 15351603
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
Int J Urol; 2006 Mar; 13(3):303-4. PubMed ID: 16643633
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
Int J Urol; 2006 Jan; 13(1):87-8. PubMed ID: 16448441
[TBL] [Abstract][Full Text] [Related]
4. Prostate adenocarcinoma metastasis in the pituitary gland.
Riemenschneider MJ; Beseoglu K; Hänggi D; Reifenberger G
Arch Neurol; 2009 Aug; 66(8):1036-7. PubMed ID: 19667229
[No Abstract] [Full Text] [Related]
5. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Masue N; Hasegawa Y
Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
[TBL] [Abstract][Full Text] [Related]
6. A case of orbital metastasis from prostatic carcinoma as an initial symptom.
Isshiki S; Cho S; Matsuno D; Sato N; Furuya Y
Hinyokika Kiyo; 2007 Mar; 53(3):193-5. PubMed ID: 17447492
[TBL] [Abstract][Full Text] [Related]
7. Metastatic prostatic adenocarcinoma presenting as a pituitary mass: shrinkage of the lesion and clinical improvement with medical treatment.
Losa M; Grasso M; Giugni E; Mortini P; Acerno S; Giovanelli M
Prostate; 1997 Sep; 32(4):241-5. PubMed ID: 9288182
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer.
Yamanaka H; Ito K; Naito S; Tsukamoto T; Usami M; Fujimoto H; Matsuoka N; Fukui I; Harada M; Ohashi Y; Kotake T; Kakizoe T
Prostate; 2005 Apr; 63(1):56-64. PubMed ID: 15468166
[TBL] [Abstract][Full Text] [Related]
9. [A case of huge prostate cancer].
Miyajima A; Ikeuchi K
Hinyokika Kiyo; 1995 Sep; 41(9):683-5. PubMed ID: 7484533
[TBL] [Abstract][Full Text] [Related]
10. Prostatic adenocarcinoma presenting with metastatic frontal bone involvement and orbital invasion.
Patel V; Castell FA; Akinwunmi J; Francis I; Chandrasekharan L; Malhotra R
Orbit; 2010 Aug; 29(4):213-5. PubMed ID: 20812840
[TBL] [Abstract][Full Text] [Related]
11. Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
Pollack A; Horwitz EM
Nat Clin Pract Oncol; 2005 Jan; 2(1):12-3. PubMed ID: 16264846
[No Abstract] [Full Text] [Related]
12. Transfusion-dependent anemia after initiation of androgen deprivation therapy for metastatic prostate cancer.
Curtis KK; Pruthi RK; Fonseca R; Gornet MK
Urology; 2007 Oct; 70(4):811.e5-8. PubMed ID: 17991572
[TBL] [Abstract][Full Text] [Related]
13. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters.
Bruchovsky N; Klotz L; Crook J; Malone S; Ludgate C; Morris WJ; Gleave ME; Goldenberg SL
Cancer; 2006 Jul; 107(2):389-95. PubMed ID: 16783817
[TBL] [Abstract][Full Text] [Related]
14. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
16. Successful recovery from interstitial pneumonitis, induced by bicalutamide and leuprorelin acetate given as treatment for prostate cancer.
Shioi K; Sakai N; Yoshida M; Nakamura M
Hinyokika Kiyo; 2005 Mar; 51(3):211-4. PubMed ID: 15852680
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
Nemoto K; Tomita Y
Scand J Urol Nephrol; 2007; 41(6):558-60. PubMed ID: 17853028
[TBL] [Abstract][Full Text] [Related]
18. [Solitary peritoneal carcinomatosis in prostate cancer].
Brehmer B; Makris A; Wellmann A; Jakse G
Aktuelle Urol; 2007 Sep; 38(5):408-9. PubMed ID: 17907070
[TBL] [Abstract][Full Text] [Related]
19. Management of hormone-sensitive metastatic prostate cancer. Update on hormonal therapy.
Figg WD; Feuer JA; Bauer KS
Cancer Pract; 1997; 5(4):258-63. PubMed ID: 9250085
[No Abstract] [Full Text] [Related]
20. Challenging problems in advanced malignancy: Case 2. Disseminated intravascular coagulation in metastatic hormone-refractory prostate cancer.
Kampel LJ
J Clin Oncol; 2003 Aug; 21(16):3170-1. PubMed ID: 12915609
[No Abstract] [Full Text] [Related]
[Next] [New Search]
